Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Textiles Press Releases.
Press releases published on May 12, 2025
Rapid7 Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Annualized recurring revenue (“ARR”) of $837 million, an increase of 4% year-over-year Total revenue of $210 million, up 3% year-over-year; Product subscriptions revenue of $204 million, up 4% year-over-year GAAP operating loss of $0.1 million; Non-GAAP …
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity Bolt is running a …
Lantronix Appoints Sailesh Chittipeddi to Its Board of Directors
GlobeNewswire
·
May 12, 2025
IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced that Sailesh Chittipeddi, Ph.D., has joined the Lantronix Board of …
Phunware Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
New Customer Launches Drive 40% Revenue Growth for Software Subscriptions and Services Strong Balance Sheet of $109.7 Million Powering R…
Viasat Announces Appointments of Bill LaPlante and Michael Paull to Its Board of Directors
GlobeNewswire
·
May 12, 2025
CARLSBAD, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications, today announced the appointments of Dr. William “Bill” LaPlante and Michael Paull to its Board of Directors, effective immediately …
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152, …
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 …
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …
TPI Composites, Inc. Announces First Quarter 2025 Earnings Results – Operational Execution and Strategic Initiatives Drive Improved Financial Results; Initiation of Strategic Review
GlobeNewswire
·
May 12, 2025
SCOTTSDALE, Ariz., May 12, 2025 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (Nasdaq: TPIC), today reported financial results for the first quarter ended March 31, 2025. TPI further announced that its Board of Directors has initiated a strategic review of the …
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 million Transaction …
BLINK CHARGING ANNOUNCES FIRST QUARTER 2025 RESULTS
GlobeNewswire
·
May 12, 2025
First quarter 2025 total revenues of $20.8 million First quarter 2025 service revenues grew 29.2% to $10.6 million compared to $8.2 million in first quarter of 2024 Gross margin of 35.5% in the first quarter of 2025 During the first quarter the Company …
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
GlobeNewswire
·
May 12, 2025
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE’26 Phase 3 CAPTIVATE trial …
EloMaas Under Review: The Wild Stallion Pro Herbal Science Breakthrough Formula to Support Sexual Health (StalliOnX)
GlobeNewswire
·
May 12, 2025
New York, May 12, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The real reasons behind common male sexual health challenges, including low stamina, reduced drive, and hormonal imbalance How EloMaas featuring Wild Stallion Pro positions itself …
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first …
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval Company to host …
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from …
Assertio Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) …
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 …
CompoSecure Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Operating results in line with expectations Reiterating previously issued full-year 2025 guidance Completed spin-off of Resolute Holdings Management, Inc. (Nasdaq: RHLD) Accounting standards related to the spin-off require the Company to report results …
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
GlobeNewswire
·
May 12, 2025
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R…